Transplantační medicína

In this panel, Dr. Stephen Gitelman facilitated the discussion with Prof Loredana Marcovecchio, Prof Holly O’Donnell, and Prof Jacques Beltrand. The speakers discussed the benefits of early detection of T1D in young people and how insights from screening initiatives can inform global programs, strategies for navigating conversations with individuals considering screening, and the importance of beta-cell preservation in the context of current and emerging therapeutic approaches.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform. 
  

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

Tıpta yaşanan gelişmeler sonucunda artık yağ dokusu veya herhangi bir yerden alınan kök hücrelerinden insülin salgılayan hücre oluşturulup büyütülebiliyor. Bu da diyabet yönetiminde kök hücre dönemini beraberinde getiriyor.

Low platelet counts are one facet of ITP, but when we look at it from another angle, we see the multiple dimensions of ITP. ITP is a condition of complex immune dysregulation that reduces platelet counts—causing bleeding, bruising, fatigue, and other health-related quality-of-life (HRQoL) issues—while increasing inflammation and the risk of thromboembolic events (TEs).^1-5

Patients reported significant quality of life (QoL) challenges related to their ITP¹